Takeda selected by major index and sustainability rating institutions concerning Corporate Social Responsibility (CSR)

Takeda selected by major index and sustainability rating institutions concerning Corporate Social Responsibility (CSR)

July 27, 2017

-       FTSE4Good Global Index (13th consecutive year)
-       Ethibel Excellence Investment Register (third time)
-       Oekom Prime Status (first time)

Osaka, Japan, July 27, 2017  –  Takeda Pharmaceutical Company Limited (TSE: 4502) announced that it has recently been selected/awarded by multiple global institutions concerning CSR.  The index, the investment universe* and the ratings are shown below;

Name of

Index/ InvestmentUniverse*/Ratings




Number of selection

FTSE4Good Global Index

FTSE Russel


13th consecutive year

Ethibel EXCELLENCE Investment Register

Forum Ethibel


three times

Oekom Prime Status



first time

The FTSE4Good Global Index is a benchmark SRI (Socially Responsible Investment)** index provided by FTSE Russell. Ethibel EXCELLENCE Investment Register is a quality mark for investment funds created by Forum Ethibel, a Belgian non-profit organization. Oekom Prime Status is awarded to companies that are among the leaders in environmental and social performance in their industries, which meet industry-specific minimum requirements according to the Oekom Corporate Rating. 

The Index, Investment Register and Sustainability Rating have been some of the most important indices for investors around the world who consider corporate social responsibility (CSR) initiatives of each company when making investment decisions. The selection process consists of reviewing Takeda’s public information such as CSR Databook and other publications. We were selected, on this occasion, in recognition of our active initiatives and information disclosures in the fields of sustainability such as the environment, society and governance.

Focusing on the patients, we believe our activities are the foundation of CSR as a pharmaceutical company committed to creating innovative new drugs. By endeavoring to maintain and enhance healthy business activities and tackling activities that increase the sustainability of society as a good corporate citizen, we practice value-creation and maintenance model. While continuing to work to support and practice Sustainable Development Goals, which are long-term global goals, Takeda will realize its mission, “We strive towards better health for people worldwide through leading innovation in medicine.”

* Investment Universe: A group of corporate brands with similar characteristics that a fund manager can incorporate into an investment portfolio.

** SRI evaluates investments in companies not only in terms of financial performance, but also with an emphasis on corporate social responsibility performance from social, ethical, environmental, and other perspectives.

FTSE4Good Global Index
Created by the global index provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indices are used by a wide variety of market participants to create and assess responsible investment funds and other products.

Ethibel Excellence Investment Register
Created by Forum Ethibel, Ethibel EXCELLENCE is a quality mark for investment funds which exclusively invest in shares or bonds included in the Investment Register and with an A, B or C rating. These are usually companies which are above average in most domains of their industry in terms of corporate social responsibility (CSR). Forum Ethibel is a Belgian non-profit organization with over 20 years’ experience in the field of rating, independent audit and certification of financial products and services that meet specific requirements in terms of ethics and sustainability.

Oekom Prime Status
he Prime Status is awarded to those companies which according to the Oekom Corporate Rating are among the leaders in environmental and social performance in their industry and which meet industry-specific minimum requirements. Oekom research has 20 years of experience in the field of sustainable investment and sustainability rating. The assessment of the social and environmental performance of a company as part of the Corporate Rating is carried out with the aid of over 100 social and environmental criteria, selected specifically for each industry, evaluating regularly around 3,700 companies.

About Takeda
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. Around 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/

Media Contacts:
Tsuyoshi Tada
[email protected]
+81 (0) 3-3278-2417